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Abstract  
A series of N-methyl-diarylamines 2 was designed and synthesized as a novel class of CA-4 and isoCA-4 analogues.  
Compounds 2b and 2m showed excellent antiproliferative activity with mean GI50 values at a nanomolar level in a 
diverse set of human cancer cell lines. These compounds also inhibited tubulin assembly at a micromolar range, arrested 
the cellular cycle in the G2/M phase and induced apoptosis at very low concentrations. Preliminary in vitro results 
revealed that 2b and 2m displayed substancial efficacy as potent antivascular agents. Docking studies indicates that 
these lead compounds showed a binding mode similar to those observed with isoCA-4 at the colchicine binding site of 
tubulin. 
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1. Introduction 
Combretastatin A-4 (CA-4) a natural stilbene isolated from the African willow tree, Combretum caffrum in 1989 by 
Pettit[1] has been found to be a potent anticancer agent which strongly inhibits tubulin assembly by binding to the 
colchicine site.[2] CA-4 also shows potent cytotoxicity against a wide range of human cancer cell lines including multi 
drugs resistant (MDR) cancer cells.[3] Moreover, CA-4 has been demonstrated to selectively target the vascular 
network of tumors, inducing irreversible shutdown of blood flow to neoplastic cells.[4] Currently, two water-soluble 
prodrug derivatives are in clinical trials: disodium phosphate CA-4P (fosbretabulin, ZybrestatTM)[5] and AVE8062 
(ombrabulin).[6] To date, CA-4P[7,8] either as a single agent or in combination therapy is undergoing several advanced 
clinical trials worldwide for the treatment of age-related macular degeneration or anaplastic thyroid cancer. 
Figure 1. Structures of CA-4 and synthetic prodrugs, isoCA-4 and derivatives, erianin, isoerianin and targeted 
azaisoerianin. 
 
Despite their remarkable anticancer properties, the main problem associated with CA-4 and its prodrugs is the ready 
isomerization of the Z-double bond into the inactive E-form during storage, administration and metabolism.[9,10]  In an 
ongoing project aimed at developing stable CA-4 analogues[11, 12, 13, 14, 15, 16, 17, 18, 19], we recently solved the 
stability problem of  CA-4 by the discovery of the non-isomerizable isocombretastatin A-4 (isoCA-4) which holds 
biological activities comparable to that of CA-4.[20, 21]. This structural isomer of the natural product, having a 1,1-
diarylethylene scaffold, is chemically and metabolically stable [22] and easy to synthesize [23, 24, 25] at a multigrams 
scale without the need to control the olefin geometry. By chemical modifications on the B-ring of isoCA-4, we have 
also identified other stable and promising antiproliferative agents [21, 26] such as isoNH2CA-4 and isoFCA-4. We next 
have demonstrated that the reduction of the 1,1-ethylene bond of isoCA-4 led to (±)-isoerianin, in which racemic and 
both enantiomers displayed excellent anti-cancer activities comparable to that of the natural isomer erianin.[27] It seems 
that the carbon (Csp3) linker in isoerianin is not involved in the interaction in the colchicine binding site. It serves only 
to position correctly the two aromatic rings of the molecule [27]. Herein, we planned to prepare a new class of 
isoerianin derivatives, named azaisoerianins (Figure 1), in which the two aromatic rings are connected through a 
nitrogen atom in place of the carbon linker in isoerianin compounds. Indeed, the diphenylamine skeleton is a common 
privileged structure found in biologically active compounds, and compounds derived from this scaffold manifest diverse 
activities, including anticancer activity.[28, 29] This design has several advantages as follow: (i) the ease in synthesis 
where various side-arms can be introduced on nitrogen atom in a convergent access, (ii) the absence of a chiral center, 
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(iii) the rapid access to weakly basic and chargeable derivatives in a solubilization strategy, (iv) the discovery of a third 
generation of candidates having promising antiproliferative and antitubulin activities and a better understanding of 
structure-activity relationships (SAR). In this article are described the synthesis and the biological evaluation of novel 
azaisoerianin derivatives 2 and 3. Preliminary in vitro efficacy of these compounds in terms of cytotoxicity, inhibition 
of tubulin assembly, cell cycle, apoptosis and in vitro antivascular activity is described. The possible binding mode of 
the most bioactive substrates 2b and 2m on tubulin is also reported. 
2. Results and discussion 
2.1. Chemistry. 
Scheme 1. Synthesis of compounds 1-3. 
 
 
aReagents and conditions: (a) Pd(OAc)2, Xantphos, ArX, Cs2CO3, dioxane, 100-130 °C, sealed tube. (b) H2, Pd/C, AcOEt. (c) NaH, MeI, DMF, RT. 
(d) HCl, MeOH, Et2O, RT. (e) Fe, HCl, EtOH/H2O. (f) Pyridine, DMAP, (Ac)2O, CH2Cl2. (g) Pd2(dba)3
.CHCl3, t-Bu2P(o-biphenyl), NHMe2, tBuONa, 
toluene, 100 °C. (h) TBAF, DMF, 100 °C. (i) NaH, nPrBr, DMF, RT. 
The synthesis of azaisoerianin derivatives 2a-q and 3a-c, is summarized in Scheme 1. Diarylanilines 1a-l were prepared 
from commercially available methoxylated anilines which were coupled in a sealed tube with a variety of aryl and 
heteroaryl halides under our previously reported conditions (Pd(OAc)2 as the catalyst, Xantphos as the ligand, Cs2CO3 
as the base in hot dioxane).[30, 31, 32, 33] Treatment of the resulting diarylamines 1 with sodium hydride followed by 
reaction with MeI gave the best results for the N-alkylation process furnishing the desired trisubstituted amines 2. By 
analogy with highly cytotoxic N-propylbenzylanilines,[34] N-propyl derivatives 3 were prepared using a large excess of 
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nPrBr as the alkylating agent and NaH as the base. Reduction of the nitro group of 2c using HCl and iron powder 
yielded azasoerianin derivative 2d with 3-amino-4-methoxy groups on the B-ring similar to the B-ring of AVE8062 
drug. Debenzylation of the phenol function of 2f was carried out by hydrogenation to afford azaisoerianin 2g having the 
greatest resemblance with isoerianin and isoCA-4. Compound 2j was synthesized from 4-chloro derivative 2i using 
dimethylamine in the presence of Pd2(dba)3.CHCl3 (5 mol%), and Johnphos (10 mol%) as the ligand and tBuONa as the 
base in hot toluene.[35] Finally, the removal of the N-protected tosyl group of 2p was accomplished by the use of 
TBAF in DMF at 100 °C to afford 2q (49%). 
2.2. Biological results. 
New synthesized azaisoerianin compounds were evaluated for their cytotoxic effects against HCT116 human carcinoma 
cell line and for tubulin polymerization inhibitory activity. Isoerianin [27], isoCA-4 [21] and CA-4 [36] were included 
as reference compounds. The cytotoxicity and inhibition of tubulin polymerization (ITP) results are presented in Table 
1. Without any exception, all secondary diarylamines 1 were not cytotoxic (data not shown).  
Table 1 Cytotoxicity against HCT 116 cellsa and ITP of selected compounds 2 and 3  
 
 
 
 
  
 
 
 
Compound 2a 2b 2b. HCl 2c 
Cytotoxicity GI50b [nM] 64 ± 4 20 ± 1.5 28 ± 2 190 ± 15 
ITP IC50c [M) 5.5 ± 0.5 2.7 ± 0.2 3± 0.2 28 ± 2 
 
 
 
 
 
   
Compound 2d 2e 2g 2h 
Cytotoxicity GI50b [nM] 66 ± 5 170 ± 12 650 ± 55 700 ± 55 
ITP IC50c [M) 3.0 ± 0.2 14 ± 1.8 1.5 ± 0.2 8.0 ± 0.5 
 
 
 
    
Compound 2j 2k 2l 2m 
Cytotoxicity GI50b [nM] 250 ± 25 650 ± 62 2100 ± 180 7± 0.6 
ITP IC50c [M] 18 ± 1.2 NAd NAd 1.3 ± 0.1 
 
 
 
  
 
Compound 2n 2o 2q 3b 
Cytotoxicity GI50b [nM] 1100 ± 120 70 ± 5 180 ± 14 1400 ± 145 
ITP IC50c [M] NAd 3.4 ± 0.5 NAd 2.8 ± 0.3 
 
 
  
 
Compound 3c isoCA-4 isoerianin CA-4 
Cytotoxicity IC50b [nM] 200 ± 16 2 ± 0.2e 28 ± 2e 2 ± 0.2e 
ITP IC50c [M] 3.6 ± 0.5 2.0 ± 0.3 3.0 ± 0.2e 1.0 ± 0.2e 
a HCT116 Human colon carcinoma. b GI50 is the concentration of compound needed to reduce cell growth by 50% following 72 h cell treatment with 
the tested drug (average of three experiments). c IC50 is the concentration of compound required to inhibit 50% of the rate of microtubule assembly 
(average of three experiments). d NA not active. e The GI50 values for isoCA-4, isoerianin and CA-4 were determined in this study. 
In the series of compounds 2 having a benzene substituted B-ring, our findings showed that compound 2b, having a 
fluorine atom at the C3’-position, displayed the best cytotoxicity with a GI50 values of 20 nM comparable to that of the 
reference isoerianin. Additionally, the water-soluble hydrochloride salt 2b-HCl displayed a high level of cytotoxicity 
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against HCT116 cells (GI50 = 28 nM) comparable to that of the parent molecule 2b (GI50 = 22 nM). Replacement of the 
F atom with H or a NH2 on the C3’-position generated compounds 2a and 2d (GI50 = 64 nM and 66 nM, respectively) 
which were three fold less active than 2b. Contrary to our expectations, a dramatic loss of antiproliferative activity was 
observed with azaisoerianin 2g, having a OH group on C3’-position.This compound and its corresponding acetate 2h 
displayed only modest cytotoxicity against HCT116 cells (GI50 = 650-700 nM). We next showed that the introduction 
of a pyridine or a quinoline nucleus as B-ring resulted in products 2k (GI50 = 650 nM) and 2l (GI50 = 2100 nM), 
respectively, with a significant loss of potency. We next investigated the role on cytotoxicity of derivatives having an 
indole nucleus which was found useful as B-ring in the CA-4 series.[37] It is significant to note that in the azaisoerianin 
series, N-methyl-indol-5-yl compound 2m was consistently the more potent compound. This lead compound (2m) was 
about four times more cytotoxic than the reference isoerianin with a low GI50 value of 7 nM. The absence of the 
trimethoxyphenyl-ring in the 5-indoyl series reduced the cytotoxicity as it was observed with compounds 2n (GI50 = 
1100 nM) and 2o (GI50 = 70 nM). Contrary to other observations, [377] the N-methyl substitution of the indole moiety 
in 2m plays an important role for the antiproliferative activity. Indeed, its des-methyl analogue 2q showed a 25-fold 
reduction in cytotoxicity. Finally, a marked loss in cytotoxicity was observed with compounds 3b (GI50 = 1400 nM) and 
3c (GI50 = 200 nM) having a N-propyl group in comparison with their N-methyl analogues (e.g. 3c vs 2m; 3b vs 2g). To 
further characterize the cytotoxicity profiles of these compounds, we next investigated the effect of the most active 
substances 2a, 2b, 2d and 2m on the proliferation of three tumor cell lines (hormone-independent breast cancer (MDA-
MB231), human glioblastoma (U87-MG), myelogenous leukemia (K562) and on the normal primary human umbilical 
vein endothelial (HUVEC). As shown in Table 2, all examined compounds displayed very potent activity against all cell 
lines tested, in the nanomolar range. Again, compound 2b and indole 2m displayed the highest level of cytotoxicity 
with GI50 values ranging from 2 to 39 nM. 
Table 2. Cytotoxicity against human cancer cell lines, HCT116, MDA-MB231, U87-MG, K562 and HUVEC.  
  Cytotoxicity (GI50 nM) a   
Compounds HCT116b MDA-MB231c U87-MG K562e HUVECf 
2a 64 ± 4 55 ± 4 30 ± 2 39 ± 4 35 ± 3 
2b 20 ± 1.5 24 ± 2 7 ± 0.6 39 ± 5 22 ± 2 
2d 66 ± 5 80 ± 7 20 ± 1.7 62 ± 5 25 ± 3 
2m 7 ± 0.6 16 ± 1.8 2.2 ± 0.3 8 ± 0.7 7 ± 0.5 
Isoerianing 28 ± 2 35 ± 3 30 ± 3 25 ± 2 45 ± 5 
a GI50 is the concentration of compound needed to reduce cell growth by 50% following 72 h cell treatment with the tested drug (average of three 
experiments). b HCT116, colon carcinoma. c MDA-MB-231 hormone-independent breast cancer. d U87-MG Glioblastoma. e K562, myelogenous 
leukaemia. f HUVEC, Human umbilical vein endothelial cells. g The GI50 values of isoerianin was determined in this study.  
To investigate whether compounds 2 and 3 exert their activities by interacting with microtubules, their effect on the in 
vitro polymerization of purified tubulin was next examined (see Table 1). It is of interest to note that highly cytotoxic 
derivatives 2b and N-methylindole 2m were also very potent as tubulin inhibitors and were comparable to isoerianin 
with IC50 micromolar values (2.7 M and 1.3 M for 2b and 2m, respectively). Interestingly, derivative 2g, having the 
greatest resemblance to isoCA-4 and isoerianin which was poorly cytotoxicity against HCT116 cells was one of the 
more potent agent as tubulin inhibitor with an IC50 value of 1.5 M. Similarly, N-propyl derivatives 3b and 3c which 
displayed a modest level of cytotoxicity were very potent in the tubulin assay with IC50 values ranging from 2.8 to 3.6 
M. These results showed an important discrepancy between the potency of antitubulin activity and cytotoxicity of N-
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propyl derivatives 3, indicating that with hindered substituents on the nitrogen atom of derivatives 3, it might be 
possible to design news series of antivascular agents with low cytoxicity. 
To gain further insight the mechanism of action of azaisoerianin derivatives 2, the most cytotoxic compounds 2b and 
2m were assayed for their effects on cell cycle distribution. K562 and HCT116 cells were treated with 2b and 2m at 
different concentrations for 24 h. The results presented in Figure 2, demonstrate that there was an accumulation of K562 
and HCT116 cells in the G2/M phase of the cellular cycle after treatment with 2b and 2m at very low concentrations. 
One note that there is a better perturbation of cycle cell progression in K562 cells after treatment with these drugs, and 
indolic derivative 2m seems to be slightly more effective than 2b in K562 and HCT116 cells. 
Figure 2. Effects of 2b and 2m on cell cycle distribution in HCT116 and K562 cells determined by flow cytometry 
analysis. DNA content was assessed via propidium iodide staining. 
HCT116 cancer cells Untreated cells 2b (10 nM) 2b (25 nM) 
 
DNA content 
K562 cancer cells Untreated cells 2b (10 nM) 2b (50 nM) 
 
DNA content 
HCT116 cancer cells Untreated cells 2m (5 nM) 2m (7.5 nM) 
 
DNA content 
K562 cancer cells  Untreated cells  2m (5 nM) 2m (7.5 nM) 
 
DNA content 
G2/M G2/M G0/G1 
G2/M 
G2/M G0/G1 G0/G1 
G2/M G2/M G0/G1 
G2/M 
G2/M G0/G1 G0/G1 
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The ability of 2b and 2m to induce apoptosis in HCT116 cells was further characterized using caspase-3 and caspase-7 
assays. The enzymatic activity of these caspases was measured by monitoring the cleavage of the fluorogenic substrate 
Z-DEVD-R110 in cancer cells. The results presented in Table 3 show a significant dose-dependent increase in 
proteolytic activity of caspases in the cells treated for 24 h with diarylmethylamines 2b and 2m. A spectacular 4-fold 
increase in apoptosis was evidenced by 2m in HCT116 cells at a low concentration of 7.5 nM. These results indicate 
that, in addition to their antiproliferative and antitubulin effects, the treatment of cancer cells with 2b and 2m activate 
caspases system leading to programmed cell death.  
Table 3. Apoptotic effects of 2b and 2m in HCT116 cells.  
Rhodamine 110 Relative Fluorescence Intensitya (% of control) 
2b 25 nM 2b 50 nM 2m 7.5 nM 2m 15 nM 
(300) (452) (393) (471) 
a The results are expressed in the percentage of apoptotic cells detected following 24 h of treatment with 2b and 2m at different concentrations. 
To identify compounds that disrupt the neovascularization formation, an assay using endothelial colony-forming cells 
(ECFCs) was performed with a panel of diarylamines 2 and 3. In the presence of the vascular endothelial growth factor 
(VEGF), ECFCs form tube-like structures that express the endothelial marker (CD31) when co-cultured on an ADSC 
feeder layer. [38] The inhibition of endothelial tube formation (IC50) was determined after 96 h of treatment using 
ECFCs, VEGF and compounds 2a-b, 2d and 2m as angiogenesis inhibitors.  
Table 4. Inhibition of endothelial tube formation using ECFCs. 
 
 
a Not Active 
 
Compounds 2k, 2l having a pyridine and quinoline B-rings respectively, as well as 2n were found to be inactive as 
angiogenesis inhibitors (Table 4). All other selected compounds inhibit the endothelial tube formation in a 
concentration-dependent manner (data not shown) with remarkable low IC50 values as for examples with 2b or 2m (CI50 
= 25 and 8 nM, respectively). One can note that N-propyl derivatives 3b and 3c which displayed a low level of 
cytotoxicity (Table 1) inhibit angiogenesis with nanomolar IC50 values of 73 and 50 nM, respectively. 
Figure 3.  
t = 0 
DMSO 2b (10 nM) 2b (100 nM) 2m (5 nM) 2m (10 nM) 
     
t = 3h 
     
  
 Inhibition of endothelial colony tube formation 
Compounds 
(IC50) nM   
2a 
56 
2b 
25 
2c 
300 
2k 
2000 
2l 
NAa 
2m 
8 
2n 
NAa 
2o 
67 
2q 
250 
3b 
73 
3c 
50 
isoerianin 
70 
isoCA-4 
7 
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These results were next confirmed by a second in vitro model of angiogenesis [39] in which human umbilical vein 
endothelial cells (HUVECs), when seeded on MatrigelTM, aggregate to form a reticular vascular network of capillary-
like vessels. The results presented in Table 2 (see above) revealed that after 72 h of incubation, 2b and 2m exhibited 
good growth inhibition activity against HUVEC cells with GI50 values of 22 and 7 nM, respectively. To evaluate 
whether 2b and 2m could affect models of newly formed blood vessels, the HUVEC tube disruption assay was 
performed. Addition of 2b at a concentration of 10 nM, and more significantly at 100 nM, rapidly disrupted the 
integrity of the network (Figure 3). This effect was visible after only 3 h of treatment at doses of 10 and 100 nM which 
were not cytotoxic for such incubation time (data not shown). This antivascular effect is even more pronounced with 
indole derivative 2m which destroyed neovascularization at a very low dose of 5 nM. All together these results 
suggested that azaisoserianin derivatives 2, and particularly 2m and 2b, might be considered and evaluated as vascular 
disrupting agents for further in vivo studies. 
2.3. Docking study. 
The biological IPT and antivascular results demonstrated that tubulin is the target of these diarylamines 2 and 3. 
Molecular docking calculations were performed with 2b and 2m in order to investigate their possible binding mode in 
the colchicine binding site of tubulin. For this purpose, the X-ray structure of tubulin DAMA-colchicine complex 
(accession code 1SA0) [40] was used. Figure 4 illustrates the docking-derived superimposition of 2b and 2m, with 
isoCA-4 (green). As expected, these diarylamines showed a binding pose matching the one calculated under the same 
conditions for isoCA-4, used as a reference compound with its A-trimethoxyphenyl ring placed in the proximity of 
Cys241. Additionally, the 4′-OMe substituent of 2b accepts a stabilizing H-bond donated by a polar hydrogen atom 
belonging to the side-chain amide moiety of Asn101. 
 
Figure 4. Calculated binding mode for 2b and 2m in the colchicine binding site of tubulin and superimposition of the 
latter with that of isoCA-4. (Central nitrogen atom and (if applicable) fluorine atom are represented as spheres in order 
to increase their visibility.) 
  
Superimposition of 2b (pink) and isoCA-4 (green) Superimposition of 2m (pink) and isoCA-4 (green) 
 
3. Conclusions 
We designed and synthesized a series of original N-methyl- and N-propyldiarylamines 2 and 3, respectively as aza-
analogues of isoerianin and isoCA-4. High inhibition of cell growth was observed with compounds 2b and 2m in a 
range of human cancer cells. These potent drugs also inhibited tubulin assembly with micromolar IC50 values. Cell 
cycle analysis of K562 and HCT116 cells treated with nanomolar concentrations of 2b and 2m indicated that cells were 
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arrested at the G2/M phase. Moreover, 2b and 2m induced apoptosis in HCT116 cells and destroyed in vitro models of 
neovasculature at very low doses. Docking studies revealed that these compounds adopted an orientation similar to that 
of isoCA-4 in the colchicine binding-site of tubulin. 
4. Experimental 
4.1 General considerations 
The compounds were all identified by usual physical methods, i.e. 1H-NMR, 13C-NMR, IR, MS. 1H and 13C NMR 
spectra were measured in CDCl3 with a Bruker Avance 300. 1H chemical shifts are reported in ppm from an internal 
standard TMS or of residual chloroform (7.27 ppm). The following abbreviations are used: m (multiplet), s (singlet), d 
(doublet), br s (broad singlet), t (triplet), dd (doublet of doublet), td (triplet of doublet). 13C chemical shifts are reported 
in ppm from the central peak of CDCl3 (77.14). IR spectra were measured on a Bruker Vector 22 spectrophotometer 
(neat, cm-1). Mass spectra were obtained with a LCT Micromass spectrometer. Analytical TLC was performed on 
Merck precoated silica gel 60F plates. Merck silica gel 60 (230-400 mesh) was used for column chromatography.  
4.2. 3,4,5-Trimethoxy-N-(4-methoxyphenyl)-N-methylaniline 2a 
In a sealed tube and under an argon atmosphere were added successively, Pd(OAc)2 (11 mg; 5 mol%), Xantphos (29 
mg; 5 mol%), 1-bromo-4-methoxybenzene (187 mg; 1 mmol), 3,4,5-trimethoxyaniline (275 mg; 1.5 mmol), Cs2CO3 
(652 mg; 2 mmol) in dioxane (2 mL). After heating at 100° C for 12 h, the resulting suspension was cooled to room 
temperature and filtered through a pad of Celite eluting with ethyl acetate, and the inorganic salts were removed. The 
filtrate was concentrated and a rapid purification by silica gel column chromatography of the residue to eliminate the 
excess of 3,4,5-trimethoxyaniline gave the desired product 1a which was immediately engaged in the alkylation step. 
1a: (75 mg, 26 %); 1H NMR (300 MHz, CDCl3)  7.04 (d, 2H, J = 9.0 Hz), 6.85 (d, 2H, J = 9.0 Hz), 6.15 (s, 2H), 5.52 
(s, 1H), 3.79 (s, 6H), 3.76 (s, 3H). 13C NMR (75 MHz, CDCl3)  155.1, 153.9 (2), 141.6, 136.1, 131.5, 121.8 (2), 114.7 
(2), 93.7 (2), 61.1, 55.9 (2), 55.6. IR (neat) νmax/ cm-1: 3278, 2993, 1600, 1501, 1224, 1124, 1007. MS (APCI) m/z: 290 
[M+H]+. To a diarylamine 1a (50 mg; 0.17 mmol) solution in DMF (2 mL) was added at 0° C, NaH (8 mg; 0.34 mmol), 
and iodomethane (48 mg; 28 L, 0.34 mmol). The mixture was stirred at r.t. for a night and diluted in EtOAc (2 mL) 
and washed with aqueous NaHCO3. The organic layer was dried, evaporated, and the residue was subjected to flash 
chromatography to give 2a as a yellow oil (35 mg, 67%). 1H NMR (300 MHz, CDCl3)  7.05 (d, 2H, J = 8.9 Hz), 6.88 
(d, 2H, J = 8.9 Hz), 6.05 (s, 2H), 3.81 (s, 3H), 3.79 (s, 3H), 3.76 (s, 6H), 3.25 (s, 3H). 13C NMR (75 MHz, CDCl3)  
155.9, 153.6 (2), 146.5, 142.5, 131.6, 125.1 (2), 114.8 (2), 95.1 (2), 61.2, 56.1 (2), 55.6, 41.0. IR (neat) νmax/ cm-1: 1575, 
1503, 1465, 1419, 1242, 1127. MS (APCI) m/z: 304 [M+H]+. HRMS calcd for C17H22NO4 [M+H]+ 304.1549, obsd. 
304.1548. 
4.3.a. N-(3-Fluoro-4-methoxyphenyl)-3,4,5-trimethoxy-N-methylaniline 2b 
By following the general procedure described above for 1a. Heating at 100 °C 3,4,5-trimethoxyaniline (275 mg; 1.5 
mmol) and 4-bromo-2-fluoro-1-methoxybenzene (205 mg; 1 mmol) for 5 h gave 1b (181 mg; 59%). 1H NMR (300 
MHz, CDCl3)  6.92-6.84 (m, 2H), 6.76 (d, 1H, J = 8.7 Hz), 6.22 (s, 2H), 5.45 (s, 1H), 3.87 (s, 3H), 3.80 (s, 9H).  13C 
NMR (75 MHz, CDCl3)  154.0 (2), 153.0 (d, J = 244.5 Hz), 142.4 (d, J = 11.2 Hz), 140.1, 137.6 (d, J = 9.0 Hz), 132.7, 
115.1 (d, J=2.2 Hz), 114.5 (d, J=2.2 Hz), 107.8 (d, J=20.2 Hz), 95.4 (2), 61.1, 57.1, 56.1 (2). 19F NMR (188 MHz, 
CDCl3)  -131.0. IR (neat) νmax/ cm-1: 1604, 1502, 1464, 1262, 1129, 1030. MS (APCI) m/z: 308 [M+H]+. By following 
the general procedure described above for 2a. Diarylamine 1b (102 mg; 0.33 mmol), NaH (12 mg; 0.5 mmol) and CH3I 
(71 mg; 0.5 mmol) gave 2b as a yellow oil (80 mg; 75%). 1H NMR (300 MHz, CDCl3)  6.87 (dd, 1H, J = 9.3 Hz, J = 
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9.0 Hz), 6.75 (dd, 1H, J = 13.3 Hz, J = 2.7 Hz), 6.71-6.66 (m, 1H), 6.18 (s, 2H), 3.84 (s, 3H), 3.80 (s, 3H), 3.76 (s, 6H), 
3.22 (s, 3H). 13C NMR (75 MHz, CDCl3)  153.6 (2), 152.7 (d, J = 243.7 Hz), 145.4, 143.4 (d, J = 8.4 Hz), 142.3 (d, J = 
11.1 Hz), 133.2, 115.9 (d, J = 2.7 Hz), 114.6 (d, J = 2.3 Hz), 109.1 (d, J = 20.5 Hz), 98.2 (2), 61.0, 56.9, 56.1 (2), 40.8. 
19F NMR (188 MHz, CDCl3)  -133.4. IR (neat) νmax/ cm-1: 2999, 1604, 1581, 1503, 1242, 1125. MS (APCI) m/z: 322 
[M+H]+. HRMS calcd for C17H21FNO4 [M+H]+ 322.1455, obsd. 322.1450. 
4.3.b. N-(3-fluoro-4-methoxyphenyl)-3,4,5-trimethoxy-N-methylbenzenaminium chloride 2b.HCl 
To a solution of 2b (97 mg; 1 mmol) in MeOH-Et2O (1:1) (10 mL) was added HClg within 10 min and then the mixture 
was stirred for 1h at RT. The precipitated salt 2b.HCl (92 mg; 86%) was isolated as green amorphous solid after 
filtration. 1H NMR (300 MHz, DMSO) δ 7.06 (t, J = 9.4 Hz, 1H), 6.83 (dd, J = 13.8, 2.5 Hz, 1H), 6.73 (d, J = 8.9 Hz, 
1H), 6.60 (s, 1H), 6.25 (s, 2H), 3.78 (s, 3H), 3.69 (s, 6H), 3.61 (s, 3H), 3.19 (s, 3H). 13C NMR (75 MHz, DMSO) δ 
153.86 (2C), 152.19 (d, J = 233.9 Hz), 145.37, 143.40 (d, J = 8.5 Hz), 141.91 (d, J = 11.1 Hz), 133.19, 116.20, 115.32, 
108.60 (d, J = 20.2 Hz), 99.00 (2C), 60.56, 56.88, 56.28 (2C), 41.02. IR (neat) νmax/ cm-1: 2999, 1612, 1521, 1488, 
1275, 1122, 1005. MS (APCI) m/z: 322 [M]+. HRMS calcd for C17H21FNO4 [M]+ 322.1449, obsd. 322.1442. 
4.4. 3,4,5-Trimethoxy-N-(4-methoxy-3-nitrophenyl)-N-methylaniline 2c 
By following the general procedure described above for 1a. Heating at 100°C 3,4,5-trimethoxyaniline (275 mg; 1.5 
mmol) and 4-iodo-1-methoxy-2-nitrobenzene (279 mg; 1 mmol) in the presence of  Pd(OAc)2 (22 mg; 10 mol%), 
Xantphos (58 mg; 10 mol%) for 1 h 30 gave 1c (307 mg; 92%). 1H NMR (300 MHz, CDCl3) 7.55 (d, 1H, J = 2.8 Hz), 
7.21 (dd, 1H, J = 9.0 Hz, J = 2.8 Hz), 7.01 (d, 1H, J = 9.0 Hz), 6.25 (s, 2H), 5.59 (s, 1H), 3.92 (s, 3H), 3.81 (s, 3H), 3.80 
(s, 6H). 13C NMR (75 MHz, CDCl3)  154.2 (2), 147.6, 140.2, 139.0, 137.3, 133.4, 124.2, 115.3, 114.9, 96.3 (2), 61.2, 
57.2, 56.2 (2). IR (neat) νmax/ cm-1: 1600, 1535, 1347, 1302, 1230, 1122, 1021. MS (APCI) m/z: 335 [M+H]+. 
By following the general procedure described above for 2a. Diarylamine 1c (167 mg; 0.5 mmol), NaH (18 mg; 0.75 
mmol) and CH3I (106 mg; 0.75 mmol) gave 2c as an orange oil (172 mg; 99%). 1H NMR (300 MHz, CDCl3)  7.41 (d, 
1H, J = 2.9 Hz), 7.09 (dd, 1H, J = 9.1 Hz, J = 2.9 Hz), 6.97 (d, 1H, J = 9.1 Hz), 6.26 (s, 2H), 3.91 (s, 3H), 3.83 (s, 3H), 
3.79 (s, 6H), 3.27 (s, 3H). 13C NMR (75 MHz, CDCl3)  154.0 (2), 146.9, 144.6, 143.0, 140.1, 134.6, 124.6, 115.0, 
114.8, 100.3 (2), 61.1, 57.2, 56.2 (2), 40.9. IR (neat) νmax/ cm-1: 1589, 1525, 1502, 1443, 1364, 1254, 1234, 1122. MS 
(APCI) m/z: 349 [M+H]+. HRMS calcd for C17H21N2O6 [M+H]+ 349.1400, obsd. 349.1392 
4.5. 4-Methoxy-N-methyl-N-(3,4,5-trimethoxyphenyl)benzene-1,3-diamine 2d 
To a (EtOH/H2O: 4/1) solution (1.5 mL) of 2c (140 mg; 0.4 mmol) were added iron (225 mg; 4 mmol) and a drop of 
HCl 12N. After refluxing for 2 h, the mixture was filtered through a pad of Celite, concentrated to give a residue which 
was subjected to flash chromatography to give 2d as a brown oil (96 mg, 76%). 1H NMR (300 MHz, CDCl3) 6.74 (d, 
1H, J = 8.3 Hz), 6.49-6.44 (m, 2H), 6.09 (s, 2H), 3.84 (s, 3H), 3.79 (s, 3H), 3.76 (s, 6H), 3.21 (s, 3H), NH2 not seen. 13C 
NMR (75 MHz, CDCl3) 153.6 (2), 146.6, 143.8, 143.2, 136.9, 131.7, 113.3, 111.3, 110.8, 95.7 (2), 61.1, 56.2 (2), 
55.9, 41.0. IR (neat) νmax/ cm-1: 1612, 1581, 1502, 1148, 1248, 1126. MS (APCI) m/z: 319 [M+H]+. HRMS calcd for 
C17H23N2O4 [M+H]+ 319.1658, obsd. 319.1654. 
4.6. N-Methyl-N-(3,4,5-trimethoxyphenyl)naphthalen-2-amine 2e 
By following the general procedure described above for 1a. Heating at 100°C 3,4,5-trimethoxyaniline (275 mg; 1.5 
mmol) and 2-iodonaphtalene (254 mg; 1 mmol) in the presence of Pd(OAc)2 (22 mg; 10 mol%), Xantphos (58 mg; 10 
mol%) for 3 h gave 1d (213 mg; 69%). 1H NMR (300 MHz, CDCl3) 7.77 (d, 2H, J = 8.5 Hz), 7.67 (d, 1H, J = 8.2 
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Hz), 7.46-7.42 (m, 2H), 7.36-7.22 (m, 2H), 6.45 (s, 2H), 5.86 (s, 1H), 3.89 (s, 3H), 3.84 (s, 6H).  13C NMR (75 MHz, 
CDCl3) 153.9 (2), 141.4, 139.2, 134.7, 133.2, 129.2, 129.1, 127.7, 126.5, 126.5, 123.5, 119.9, 111.5, 96.4 (2), 61.1, 
56.1 (2). IR (neat) νmax/ cm-1: 1631, 1596, 1503, 1465, 1223, 1127, 1006. MS (APCI) m/z: 310 [M+H]+. By following 
the general procedure described above for 2a. Diarylamine 1d (155 mg; 0.5 mmol), NaH (18 mg; 0.75 mmol) and CH3I 
(106 mg; 0.75 mmol) gave 2e as a yellow oil (140 mg; 87%). 1H NMR (300 MHz, CDCl3) 7.72 (t, 2H, J = 7.8 Hz ), 
7.66 (d, 1H, J = 9.0 Hz), 7.45-7.39 (td, 1H, J = 8.6 Hz, J = 1.3 Hz), 7.33-7.28 (m, 1H), 7.25 (d, 1H, J = 2.5 Hz), 7.17 
(dd, 1H, J = 8.9 Hz, J = 2.4 Hz ), 6.39 (s, 2H), 3.87 (s, 3H), 3.79 (s, 6H), 3.41 (s, 3H).  13C NMR (75 MHz, CDCl3) 
153.9 (2), 146.9, 145.4, 134.8, 134.4, 128.7, 128.5, 127.6, 126.7, 126.4, 123.5, 121.0, 112.5, 100.9 (2), 61.1, 56.2 (2), 
41.0. IR (neat) νmax/ cm-1: 1629, 1589, 1502, 1240, 1128, 1005. MS (APCI) m/z: 324 [M+H]+. HRMS calcd for 
C20H22NO3 [M+H]+ 324.1600, obsd. 324.1602. 
 
4.7. N-(3-(benzyloxy)-4-methoxyphenyl)-3,4,5-trimethoxy-N-methylaniline 2f 
Compound 2f was prepared from diarylaniline 1e (yield 61%) according to literature [41]. 1H NMR (300 MHz, CDCl3) 
7.40-7.27 (m, 5H), 6.86 (d, 1H, J = 8.4 Hz), 6.67-6.62 (m, 2H), 6.06 (s, 2H), 5.08 (s, 2H), 3.88 (s, 3H), 3.81 (s, 3H), 
3.72 (s, 6H), 3.20 (s, 3H). 13C NMR (75 MHz, CDCl3) 153.6 (2), 148.7, 146.1, 145.8, 142.9, 137.1, 128.6 (2), 127.9, 
127.4 (2), 115.1, 112.9, 110.1, 96.2 (2), 71.1, 61.1, 56.5, 56.1 (2), 41.0. IR (neat) νmax/ cm-1: 1579, 1502, 1452, 1411, 
1230, 1125. MS (ESI) m/z: 432.3 [M+Na]+. HRMS calcd for C24H28NO5 [M+H]+ 410.1967, obsd. 410.1964. 
4.8. AzaisoCA-4 2g 
Compound 2g was prepared from diarylaniline 2f using H2 and Pd/C (10 mol%) in EtOAc (yield 98%) according to 
literature[41]. 1H NMR (300 MHz, CDCl3) 6.79 (d, 1H, J = 8.7 Hz), 6.67 (d, 1H, J = 2.7 Hz), 6.53 (dd, 1H, J = 8.7 
Hz, J = 2.7 Hz), 6.14 (s, 2H), 5.64 (s, 1H), 3.87 (s, 3H), 3.80 (s, 3H), 3.77 (s, 6H), 3.22 (s, 3H). 13C NMR (75 MHz, 
CDCl3) 153.6 (2), 146.3, 146.1, 143.7, 142.3, 132.4, 113.4, 111.5, 109.2, 97.0 (2), 61.1, 56.4, 56.2 (2), 41.0.  IR (neat) 
νmax/ cm-1: 2959, 1581, 1501, 1447, 1249. MS (APCI) m/z: 342 [M+Na]+. HRMS calcd for C17H22NO5 [M+H]+ 
320.1498, obsd. 320.1494. 
4.9. 2-Methoxy-5-(methyl(3,4,5-trimethoxyphenyl)amino)phenyl acetate 2h 
At 0° C, to a solution of 2g (101 mg; 0.316 mmol) in CH2Cl2 (1 mL) were added pyridine (54 L), and DMAP (0.016 
mmol) and Ac2O (42 L). After one hour of stirring, H2O (3 mL) was added to the mixture. After extraction with 
EtOAc (3 x 3 mL), the organic layer was dried, evaporated, and the residue was subjected to flash chromatography to 
give 2h as a yellow oil (76 mg, 67%). 1H NMR (300 MHz, CDCl3) δ 6.92-6.84 (m, 2H),, 6.75 (d, J = 2.4 Hz, 1H), 6.17 
(s, 2H), 3.80 (s, 6H), 3.77 (s, 6H), 3.24 (s, 3H), 2.28 (s, 3H). 13C NMR (75 MHz, CDCl3) 169.0, 153.7 (2), 146.4, 
145.7, 142.9, 140.2, 132.8, 119.3, 116.8, 113.3, 97.4 (2), 61.1, 56.4, 56.2 (2), 40.9, 20.7. IR (neat) νmax/ cm-1: 1721, 
1574, 1452, 1375, 1204. MS (ESI) m/z: 362 [M+H]+. HRMS calcd for C19H23NO6Na [M+Na]+ 384.1423, obsd. 
384.1426. 
4.10. N-(4-Chlorophenyl)-3,4,5-trimethoxy-N-methylaniline 2i 
By following the general procedure described above for 1a. Heating at 100°C 3,4,5-trimethoxyaniline (275 mg; 1.5 
mmol) and 1-chloro-4-iodobenzene (59 mg; 0.25 mmol) in the presence of Pd(OAc)2 (22 mg; 10 mol%), Xantphos (58 
mg; 10 mol%) for 12 h gave 1f as an orange solid (40 mg; 55%). m.p. = 109 °C. 1H NMR (300 MHz, CDCl3) 7.20 (d, 
2H, J = 8.9 Hz), 6.95 (d, 2H, J = 8.9 Hz), 6.30 (s, 2H), 3.82 (s, 3H), 3.80 (s, 6H), NH not seen.  13C NMR (75 MHz, 
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CDCl3) 154.0 (2), 142.5, 138.9, 133.3, 129.4 (2), 125.3, 118.6 (2), 96.8 (2), 61.1, 56.1 (2). IR (neat) νmax/ cm-1: 1611, 
1590, 1508, 1228, 1119. MS (APCI) m/z: 294, 296 [M+H]+. By following the general procedure described above for 2a. 
Diarylamine 1f (29 mg; 0.1 mmol), NaH (5 mg; 0.2 mmol) and CH3I (28 mg; 0.2 mmol) gave 2i as a yellow-orange 
solid (27 mg; 88%). m.p. = 91 °C. 1H NMR (300 MHz, CDCl3) 7.17 (d, 2H, J = 8.5 Hz), 6.82 (d, 2H, J = 8.5 Hz), 
6.31 (s, 2H), 3.84 (s, 3H), 3.79 (s, 6H), 3.26 (s, 3H). 13C NMR (75 MHz, CDCl3) 153.9 (2), 147.9, 144.8, 134.6, 129.0 
(2), 124.6, 118.9 (2), 101.0 (2), 61.0, 56.1 (2), 40.6. IR (neat) νmax/ cm-1: 2999, 1609, 1579, 1510, 1451, 1237.  
4.11. N,N,N’-Trimethyl-N’-(3,4,5-trimethoxyphenyl)benzene-1,4-diamine 2j 
In a sealed tube and under an argon atmosphere were added successively, Pd2(dba)3.CHCl3 (52 mg; 5 mol%), Johnphos 
(30 mg; 10 mol%), dimethylamine (large excess), 2i (307 mg; 1 mmol), NaOtBu (134 mg; 1.4 mmol) in toluene (10 
mL). After heating at 100° C for 24 h, the resulting suspension was cooled to room temperature and filtered through a 
pad of Celite eluting with ethyl acetate, and the inorganic salts were removed. The filtrate was concentrated and a rapid 
purification by silica gel column chromatography of the residue to eliminate the excess of 3,4,5-trimethoxyaniline gave 
the desired product 2j as a white solid (98 mg, 31 %). m.p. = 75 °C. 1H NMR (300 MHz, CDCl3) 7.05 (d, 2H, J = 7.3 
Hz), 6.75 (d, 2H, J = 7.3 Hz), 6.01 (s, 2H), 3.78 (s, 3H), 3.76 (s, 6H), 3.24 (s, 3H), 2.95 (s, 6H).  13C NMR (75 MHz, 
CDCl3) 153.6 (2), 147.9, 147.8, 146.9, 139.1, 126.0 (2), 113.9 (2), 93.8 (2), 61.2, 56.1 (2), 41.1 (2), 41.0.  IR (neat) 
νmax/ cm-1: 1611, 1583, 1504, 1128. MS (ESI) m/z: 339 [M+Na]+. HRMS calcd for C18H25N2O3 [M+H]+ 317.1865, obsd. 
317.1860. 
4.12. 6-Methoxy-N-methyl-N-(3,4,5-trimethoxyphenyl)pyridin-3-amine 2k 
By following the general procedure described above for 1a. Heating at 100°C 3,4,5-trimethoxyaniline (275 mg; 1.5 
mmol) and 5-bromo-2-methoxypyridine (187 mg; 1 mmol) in the presence of Pd(OAc)2 (11 mg; 5 mol%), Xantphos (29 
mg; 5 mol%) for 5 h gave 1g as a yellow oil (160 mg; 54%). 1H NMR (300 MHz, CDCl3) 7.98 (d, 1H, J = 2.3 Hz), 
7.42 (dd, 1H, J = 8.8 Hz, J = 2.8 Hz), 6.72 (d, 1H, J = 8.8 Hz), 6.10 (s, 2H), 5.36 (s, 1H), 3.92 (s, 3H), 3.79 (s, 3H), 3.78 
(s, 6H). 13C NMR (75 MHz, CDCl3) 160.1, 154.1 (2), 141.2, 139.0, 133.5, 133.1, 132.2, 111.2, 93.9 (2), 61.2, 56.2 (2), 
53.8. IR (neat) νmax/ cm-1: 1599, 1486, 1367, 1230, 1125, 1028. MS (APCI) m/z: 291 [M+H]+.  By following the general 
procedure described above for 2a. Diarylamine 1g (290 mg; 1 mmol), NaH (48 mg; 2 mmol) and CH3I (284 mg; 2 
mmol) gave 2k as a yellow oil (267 mg; 88%). 1H NMR (300 MHz, CDCl3) 7.93 (d, 1H, J = 2.8 Hz), 7.34 (dd, 1H, J 
= 8.8 Hz, J = 2.8 Hz), 6.68 (d, 1H, J = 8.8 Hz), 6.03 (s, 2H), 3.90 (s, 3H), 3.76 (s, 3H), 3.74 (s, 6H), 3.22 (s, 3H).  13C 
NMR (75 MHz, CDCl3) 160.2, 153.7 (2), 145.8, 141.2, 139.7, 134.9, 132.2, 111.2, 95.6 (2), 61.0, 56.1 (2), 53.6, 41.0. 
IR (neat) νmax/ cm-1: 1587, 1491, 1275, 1235, 1127, 1028. MS (APCI) m/z: 305 [M+H]+. HRMS calcd for C16H21N2O4 
[M+H]+ 305.1501, obsd. 305.1501. 
4.13. N-Methyl-N-(3,4,5-trimethoxyphenyl)quinolin-3-amine 2l 
By following the general procedure described above for 1a. Heating at 100°C 3,4,5-trimethoxyaniline (275 mg; 1.5 
mmol) and 3-bromoquinoline (207 mg; 1 mmol) in the presence of Pd(OAc)2 (44 mg; 20 mol%), Xantphos (29 mg; 5 
mol%) and Cs2CO3 (534 mg; 1.64 mmol) for 3 h gave 1h as a yellow oil (167 mg; 54%). 1H NMR (300 MHz, CDCl3) 
8.69 (d, 1H, J = 2.7 Hz), 8.00-7.97 (m, 1H), 7.64 (d, 1H, J = 2.7 Hz), 7.61-7.58 (m, 1H), 7.50-7.40 (m, 2H), 6.41 (s, 
3H), 3.84 (s, 3H), 3.77 (s, 6H). 13C NMR (75 MHz, CDCl3) 154.0 (2), 144.9, 143.4, 138.2, 137.8, 133.6, 129.0, 129.0, 
127.2, 126.4 (2), 116.7, 97.1 (2), 61.1, 56.1 (2). IR (neat) νmax/ cm-1: 3338, 1602, 1506, 1237, 1124. MS (APCI) m/z: 
311 [M+H]+. By following the general procedure described above for 2a. Diarylamine 1h (155 mg; 0.5 mmol), NaH (18 
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mg; 0.75 mmol) and CH3I (107 mg; 0.75 mmol) gave 2l as a yellow oil (110 mg; 68%). 1H NMR (300 MHz, CDCl3) 
8.62 (d, 1H, J = 2.8 Hz), 8.00-7.94 (m, 1H), 7.68-7.63 (m, 1H), 7.51-7.42 (m, 2H), 7.39 (d, 1H, J = 2.8 Hz), 6.38 (s, 
2H), 3.85 (s, 3H), 3.78 (s, 6H), 3.38 (s, 3H). 13C NMR (75 MHz, CDCl3) 154.1 (2), 145.4, 144.2, 142.7, 142.6, 135.2, 
129.0, 127.1, 126.5, 126.3, 117.3, 101.5 (2), 61.1, 56.2 (2), 40.82 (one C missing). IR (neat) νmax/ cm-1: 1588, 1504, 
1245, 1229, 1128. MS (APCI) m/z: 325 [M+H]+.  
4.14. N,1-Dimethyl-N-(3,4,5-trimethoxyphenyl)-1H-indol-5-amine 2m 
To an Emrys Optimizer were added 3,4,5-trimethoxyaniline (260 mg; 1.42 mmol), 6-bromo-1-methyl-1H-indole (150 
mg; 0.71 mmol), Pd(OAc)2 (16 mg; 10 mol%), Xantphos (41 mg; 10 mol%), Cs2CO3 (463 mg; 1.42 mmol) in dioxane 
(5 mL). The reaction vessel was then placed in the Emrys Optimizer and exposed to microwave irradiation according to 
the following specifications: temperature: 130°C, time: 3h, fixed hold time: on, sample absorption: high, pre-stirring: 60 
s. After cooling to room temperature, the mixture was filtered through a pad of Celite eluting with ethyl acetate, and the 
inorganic salts were removed. The filtrate was concentrated and a rapid purification by silica gel column 
chromatography of the residue to eliminate the excess of 3,4,5-trimethoxyaniline gave the desired product 1i as a yellow 
oil which was immediately engaged in the alkylation step. 1i: (108 mg, 49 %); 1H NMR (300 MHz, CDCl3)  7.35 (s, 
1H), 7.23 (s, 1H), 7.05-7.02 (m, 2H), 6.38 (d, 1H, J = 3.0 Hz), 6.15 (s, 2H), 5.50 (brs, 1H), 3.77 (s, 3H), 3.76 (s, 3H), 
3.74 (s, 6H). 13C NMR (75 MHz, CDCl3) 154.0 (2), 143.0, 135.1, 133.8, 131.3, 129.6, 129.2, 117.9, 113.4, 110.0, 
100.6, 93.3 (2), 61.2, 56.1 (2), 33.1. IR (neat) νmax/ cm-1: 3370, 1605, 1505, 1247, 1125, 1009. MS (APCI) m/z: 313 
[M+H]+. By following the general procedure described above for 2a. Diarylamine 1i (31 mg; 0.1 mmol), NaH (12 mg; 
0.5 mmol) and CH3I (71 mg; 0. 5 mmol) gave 2m as a yellow oil (21 mg; 65%). 1H NMR (300 MHz, CDCl3) 7.43 (d, 
1H, J = 2.0 Hz), 7.30 (d, 1H, J = 8.6 Hz), 7.08-7.05 (m, 2H), 6.45 (d, 1H, J = 3.0 Hz), 6.03 (s, 2H), 3.81 (s, 3H), 3.80 (s, 
3H), 3.74 (s, 6H), 3.33 (s, 3H). 13C NMR (75 MHz, CDCl3) 153.5 (2), 147.4, 141.7, 134.4, 130.7, 129.6, 129.3, 120.7, 
117.4, 110.1, 101.0, 93.6 (2), 61.1, 56.1 (2), 41.5, 33.1. IR (neat) νmax/ cm-1: 1602, 1581, 1505, 1490, 1418, 1234, 1123. 
MS (APCI) m/z: 327 [M+H]+. HRMS calcd for C19H23N2O3 [M+H]+ 327.1709, obsd.327.1698. 
4.15. N-(4-Methoxyphenyl)-N,1-dimethyl-1H-indol-5-amine 2n 
By following the general procedure described above for 1i. Heating at 130°C under microwave irradiation 4-
methoxyaniline (123 mg; 1 mmol) and 6-bromo-1-methyl-1H-indole (105 mg; 0.5 mmol) for 3 h gave 1j as a yellow oil 
(50 mg; 40%). 1H NMR (300 MHz, CDCl3) 7.37 (d, 1H, J = 1.7 Hz), 7.30 (d, 1H, J = 8.7 Hz), 7.08-7.02 (m, 4H), 
6.94-6.89 (m, 2H), 6.47 (d, 1H, J = 3.0 Hz), 5.31 (br s, 1H), 3.86 (s, 3H), 3.79 (s, 3H). 13C NMR (75 MHz, CDCl3) 
153.7, 139.5, 136.9, 133.2, 129.4, 129.2, 118.6 (2), 116.2, 114.7 (2), 110.6, 109.8, 100.3, 55.7, 32.9. IR (neat) νmax/ 
cm-1: 1618, 1571, 1509, 1422, 1240. MS (APCI) m/z: 253 [M+H]+.By following the general procedure described above 
for 2a. Diarylamine 1j (63 mg; 0.25 mmol), NaH (12 mg; 0.5 mmol) and CH3I (71 mg; 0.5 mmol) gave 2n as a white 
solid (34 mg; 51%). m.p. = 113 °C; 1H NMR (300 MHz, CDCl3) 7.25 (d, 1H, J = 1.9 Hz), 7.17-7.14 (m, 1H), 6.94 (d, 
1H, J = 2.9 Hz), 6.90 (dd, 1H, J = 8.7 Hz, J = 2.0 Hz), 6.78-6.69 (m, 4H), 6.32 (d, 1H, J = 3.0 Hz), 3.68 (s, 6H), 3.20 (s, 
3H). 13C NMR (75 MHz, CDCl3) 153.4, 144.9, 143.0, 133.7, 129.5, 129.3, 119.2 (2), 119.1, 114.8, 114.6 (2), 110.0, 
100.8, 55.8, 41.8, 33.0. IR (neat) νmax/ cm-1: 1620, 1508, 1487, 1422, 1234, 1031. MS (APCI) m/z: 267 [M+H]+. HRMS 
calcd for C17H19N2O [M+H]+ 267.1497, obsd. 267.1494.
4.16. N-(3,5-Dimethoxyphenyl)-N,1-dimethyl-1H-indol-5-amine 2o 
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By following the general procedure described above for 1i. Heating at 130°C under microwave irradiation 3,5-
dimethoxyaniline (153 mg; 1 mmol) and 6-bromo-1-methyl-1H-indole (105 mg; 0.5 mmol) for 3 h gave 1k as a yellow 
oil (35 mg; 25%). 1H NMR (300 MHz, CDCl3) 7.45 (d, 1H, J = 1.9 Hz), 7.30 (d, 1H, J = 9.4 Hz), 7.13-7.07 (m, 2H), 
6.45 (d, 1H, J = 3.0 Hz), 6.14 (d, 2H, J = 2.1 Hz), 6.01 (t, 1H, J = 2.1 Hz), 5.68 (br s, 1H), 3.81 (s, 3H), 3.76 (s, 6H). 
13C NMR (75 MHz, CDCl3) 161.2 (2), 148.7, 134.2, 134.1, 129.6, 129.1, 118.6, 114.5, 109.9, 100.7, 93.6 (2), 91.3, 
55.3 (2), 33.0. IR (neat) νmax/ cm-1: 1592, 1518, 1448, 1154. MS (APCI) m/z: 305 [M+Na]+. By following the general 
procedure described above for 2a. Diarylamine 1k (28 mg; 0.1 mmol), NaH (12 mg; 0.5 mmol) and CH3I (71 mg; 0.5 
mmol) gave 2o as a yellow oil (27 mg; 93%). 1H NMR (300 MHz, CDCl3) 7.47 (d, 1H, J = 2.0 Hz), 7.32 (d, 1H, J = 
8.6 Hz), 7.09 (d, 2H, J = 6.9 Hz, J = 2.5 Hz), 6.46 (d, 1H, J = 3.1 Hz), 5.94 (s, 3H), 3.81 (s, 3H), 3.70 (s, 6H), 3.32 (s, 
3H). 13C NMR (75 MHz, CDCl3) 161.4 (2), 152.5, 141.2, 134.8, 129.6, 129.3, 121.5, 118.9, 110.2, 101.1, 93.6 (2), 
89.6, 55.3 (2), 41.2, 33.1. IR (neat) νmax/ cm-1: 3433, 1608, 1578, 1419, 1236, 1138. MS (APCI) m/z: 297 [M+H]+. 
HRMS calcd for C18H21N2O2 [M+H]+ 297.1603, obsd. 297.1601. 
4.17. N-Methyl-1-(phenylsulfonyl)-N-(3,4,5-trimethoxyphenyl)-1H-indol-5-amine 2p 
By following the general procedure described above for 1i. Heating at 130°C under microwave irradiation 3,4,5-
trimethoxyaniline (183 mg; 1 mmol) and 5-bromo-1-(phenylsulfonyl)-1H-indole (167 mg; 0.5 mmol) for 4 h gave 1l as 
a yellow oil (162 mg; 74%). 1H NMR (300 MHz, CDCl3) 7.89-7.84 (m, 3H), 7.53-7.47 (m, 2H), 7.43-7.37 (m, 2H), 
7.17 (d, 1H, J = 2.0 Hz), 7.02 (dd, 1H, J = 2.1 Hz, J = 8.8 Hz), 6.53 (dd, 1H, J = 3.6 Hz, J = 0.5 Hz), 6.26 (s, 2H), 5.74 
(s, 1H), 3.80 (s, 3H), 3.74 (s, 6H). 13C NMR (75 MHz, CDCl3) 153.9 (2), 140.3, 139.8, 138.2, 133.8, 132.5, 131.9, 
130.2, 129.2 (2), 127.0, 126.7 (2), 117.4, 114.3, 109.9, 109.3, 95.6 (2), 61.0, 56.0 (2).  IR (neat) νmax/ cm-1: 2927, 1600, 
1504, 1450, 1336, 1227. MS (ESI) m/z: 461 [M+Na]+.By following the general procedure described above for 2a. 
Diarylamine 1l (110 mg; 0.25 mmol), NaH (12 mg; 0.5 mmol) and CH3I (71 mg; 0. 5 mmol) gave 2p as a yellow oil (81 
mg; 72%). 1H NMR (300 MHz, CDCl3) 7.89-7.86 (m, 3H), 7.55-7.50 (m, 2H), 7.42 (dd, 2H, J = 10.4 Hz, J = 4.7 Hz ), 
7.13 (d, 1H, J = 2.2 Hz), 7.02 (dd, 1H, J = 8.9 Hz, J = 2.2 Hz ), 6.57 (d, 1H, J = 3.6Hz), 6.16 (s, 2H), 3.82 (s, 3H), 3.73 
(s, 6H), 3.28 (s, 3H). 13C NMR (75 MHz, CDCl3) 153.7 (2), 146.1, 145.7, 138.3, 133.8, 133.0, 131.9, 130.4, 129.3 (2), 
127.0, 126.8 (2), 119.6, 114.2, 112.7, 109.4, 98.0 (2), 61.1, 56.1 (2), 41.2. IR (neat) νmax/ cm-1: 1586, 1504, 1446, 1368, 
1123. MS (ESI) m/z: 453 [M+H]+, 475 [M+Na]+ . HRMS calcd for C25H27N2O5S [M+H]+ 453.1484, obsd.453.1487.
4.18. NN-Methyl-N-(3,4,5-trimethoxyphenyl)-1H-indol-5-amine 2q 
A THF (1 mL) solution of 2p (47 mg; 0.1 mmol) was added 0.5 mL of a TBAF solution in THF (0.5 mmol) and stirred 
at 100 °C for 6 h. After cooling, the solution was filtered through a pad of Celite, eluting with ethyl acetate. The filtrate 
was concentrated and a purification by silica gel column chromatography gave the desired product 2q as a white solid 
(15 mg, 49 %). m.p. 166 °C. 1H NMR (300 MHz, CDCl3)  8.34 (s, 1H), 7.44 (s, 1H), 7.36 (d, 1H, J = 8.6 Hz), 7.22 (t, 
1H, J = 2.7 Hz), 7.02 (dd, 1H, J = 8.6 Hz, J = 1.9 Hz), 6.52-6.51 (m, 1H), 6.04 (s, 2H), 3.80 (s, 3H), 3.74 (s, 6H), 3.33 
(s, 3H). 13C NMR (75 MHz, CDCl3) 153.6 (2), 147.4, 142.1, 133.4, 130.8, 128.8, 125.1, 121.0, 117.1, 112.0, 102.7, 
93.8 (2), 61.2, 56.1 (2), 41.5. IR (neat) νmax/ cm-1: 3433, 1608, 1578, 1505, 1450, 1419, 1236. MS (ESI) m/z: 335 
[M+Na]+. HRMS calcd for C18H21N2O3 [M+H]+ 313.1552, obsd. 331.1548. 
4.19. N-(3-(benzyloxy)-4-methoxyphenyl)-3,4,5-trimethoxy-N-propylaniline 3a 
To a diarylamine 1e (197 mg; 0.5 mmol) solution in DMF (5 mL) was added at 0° C, NaH (24 mg; 1 mmol), and 1-
bromopropane (122 mg; 1 mmol). The mixture was stirred at r.t. for 2 h, diluted in EtOAc (5 mL) and washed with 
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aqueous NaHCO3. The organic layer was dried, evaporated, and the residue was subjected to flash chromatography to 
give 3a as a brown oil (208 mg, 95%). 1H NMR (300 MHz, CDCl3)  7.40-7.27 (m, 5H), 6.86-6.83 (m, 1H), 6.63-6.59 
(m, 2H), 6.00 (s, 2H), 5.09 (s, 2H), 3.89 (s, 3H), 3.80 (s, 3H), 3.71 (s, 6H), 3.50-3.44 (m, 2H), 1.61-1.59 (m, 2H), 0.89 
(t, 3H, J = 7.4 Hz). 13C NMR (75 MHz, CDCl3) 153.7 (2), 148.7, 145.8, 145.4, 141.6, 137.1, 131.8, 128.6 (2), 127.9, 
127.4 (2), 116.0, 112.8, 111.0, 96.3 (2), 71.1, 61.2, 56.5, 56.1 (2), 54.7, 21.0, 11.6.  IR (neat) νmax/ cm-1: 2925, 1610, 
1502, 1464, 1225, 1127. MS (APCI) m/z: 438 [M+H]+. HRMS calcd for C26H32NO5 [M+H]+ 438.2280, obsd. 438.2285. 
4.20. 2-methoxy-5-(propyl(3,4,5-trimethoxyphenyl)amino)phenol 3b 
3b brown oil (140 mg; 99%) was prepared by following the general procedure described above for 2g. 1H NMR (300 
MHz, CDCl3) 6.78 (d, 1H, J = 8.7 Hz), 6.65 (d, 1H, J = 2.6 Hz), 6.51 (dd, 1H, J = 8.7 Hz, J = 2.6 Hz ), 6.11 (s, 2H), 
5.60 (s, 1H), 3.88 (s, 3H), 3.81 (s, 3H), 3.77 (s, 6H), 3.57-3.52 (m, 2H), 1.70-1.60 (m, 2H), 0.94 (t, 3H, J = 7.4 Hz). 13C 
NMR (75 MHz, CDCl3) 153.7 (2), 146.3, 145.2, 142.6, 142.2, 132.3, 114.1, 111.6, 109.7, 97.5 (2), 61.2, 56.4, 56.2 
(2), 54.7, 21.0, 11.6. IR (neat) νmax/ cm-1: 2959, 1581, 1501, 1466, 1261, 1126, 1027. MS (ESI) m/z: 370 [M+Na]+. 
HRMS calcd for C19H26NO5 [M+H]+ 348.1811, obsd. 348.1812. 
4.21. 1-Methyl-N-propyl-N-(3,4,5-trimethoxyphenyl)-1H-indol-5-amine 3c 
3c yellow oil (120 mg; 34%) was prepared from 1i by following the general procedure described above for 3a. 1H NMR 
(300 MHz, CDCl3) 7.45 (d, 1H, J = 1.7 Hz), 7.32 (d, 1H, J = 8.6 Hz), 7.08-7.05 (m, 2H), 6.47 (d, 1H, J = 3.0 Hz), 
5.99 (s, 2H), 3.81 (s, 6H), 3.73 (s, 6H), 3.66 (t, 2H, J = 6.5 Hz), 1.76-1.60 (m, 2H), 0.97 (t, 3H, J = 7.4 Hz). 13C NMR 
(75 MHz, CDCl3) 153.5 (2), 146.7, 139.9, 134.5, 130.2, 129.4, 129.3, 121.8, 118.7, 110.1, 100.9, 93.3 (2), 61.1, 56.0 
(2), 55.0, 33.0, 21.0, 11.6. IR (neat) νmax/ cm-1: 1606, 1580, 1507, 1487, 1237, 1125. MS (ESI) m/z: 377 [M+Na]+. 
HRMS calcd for C21H27N2O3 [M+H]+ 355.2022, obsd. 355.2018. 
 
4.3. Biolology 
4.3.1. Cell Culture and Proliferation Assay 
Cancer cell lines were obtained from the American type Culture Collection (Rockville, MD) and were cultured 
according to the supplier’s instructions. Briefly, A549 lung carcinoma, U87-MG human glioblastoma, MDA-MB231 
cells were grown in Dulbecco minimal essential medium (DMEM) containing 4.5 g/L glucose supplemented with 10% 
FCS and 1% glutamine. Human K562 leukemia and HCT116 colorectal carcinoma cells were grown in RPMI 1640 
containing 10% FCS and 1% glutamine. Human umbilical vein endothelial cells (HUVECs) were obtained from 
Clonetics (Lonza, Walkersville, MD, USA) and cultured according to the supplier’s instructions. Briefly, HUVECs 
from three to six passages were subcultured to confluence onto 0.2% gelatin coated tissue culture flasks in endothelial 
cell growth medium (EGM2) containing growth factors and 2% FCS. All cell lines were maintained at 37 °C in a 
humidified atmosphere containing 5% CO2. Cell viability was assessed using Promega CellTiter-Blue TM reagent 
according to the manufacturer’s instructions. Cells were seeded in 96-well plates (5 × 103 cells/well) containing 50 μL 
growth medium. After 24 h of culture, the cells were supplemented with 50 μL of the tested compound dissolved in 
DMSO (less than 0.1% in each preparation). After 72 h of incubation, 20 μL of resazurin was added for 2 h before 
recording fluorescence (λex = 560 nm, λem = 590 nm) using a Victor microtiter plate fluorimeter (Perkin-Elmer,USA). 
The IC50 corresponds to the concentration of the tested compound that caused a decrease of 50% in fluorescence of 
drug treated cells compared with untreated cells. Experiments were performed in triplicate. 
 
4.3.2. Tubulin Binding Assay 
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Sheep brain tubulin was purified according to the method of Shelanski [42] by two cycles of assembly-disassembly and 
then diluted in the assembly buffer containing 0.1 M MES, 0.5 mM MgCl2, 1 mM EGTA, and 1 mM GTP, pH 6.6 to a 
final concentration around 2-3 mg/mL. Tubulin assembly was monitored by fluorescence according to reported 
procedure [43] using DAPI as fluorescent molecule. Assays were realized on 96-well plates prepared with Biomek 
NKMC and Biomek 3000 from Beckman Coulter and read at 37°C on Wallac Victor fluorimeter from Perkin Elmer. 
The IC50 value of each compound was determined as the concentration required to decrease the maximum assembly rate 
of tubulin by 50% compared to the rate in the absence of compound. The IC50 values for all compounds were compared 
to the IC50 of isoCA-4 and isoerianin measured the same day under the same conditions. 
 
4.3.2. Cell Cycle Analysis  
Exponentially growing cancer cells (K562, HCT116) were incubated with tested compound or DMSO for 24 h. Cell-
cycle profiles were determined by flow cytometry on a FC500 flow cytometer (Beckman-Coulter, France) as described 
previously.[44] 
 
4.3.3. Apoptosis Assay 
Apoptosis was measured by the Apo-one homogeneous caspase-3/7 assay (Promega Co, WI) according to the 
manufacturer’s recommendations. Briefly, cells were subcultured on a 96-well plate with 5 × 104 cells/well in 100 μL 
medium. After 24 h of incubation, the medium in the 96-well plate was discarded and replaced with medium containing 
different concentrations of 2b and 2m (7.5, 15, 25 and 50 nM). The treated cells were incubated for 24 h, each well then 
received 100 μL of a mixture of caspase substrate and Apo-one caspase 3/7 buffer. After 1 h of incubation, the 
fluorescence of sample was measured using a Victor microtiter plate fluorimeter (Perkin-Elmer, USA) at 527 nm. 
 
4.3.4. Inhibition of endothelial tube formation using ECFCs. 
The protocol was achieved according to ref. [38]. 
 
4.3.5. Cord Disruption Assay 
HUVECs (2 × 104 cells per well) were plated in 96-well plates on a thick layer of Matrigel (Becton Dickinson; 10 mg 
mL-1, 60 µL per well) and allowed to align for 24 h. 2b, 2m or vehicle (DMSO) were added to the formed cords and left 
for 3 h. Images were taken 3 h after the addition of compounds. 
 
4.3.6. Molecular Modelling  
Coordinates for compounds 2b, 2m and isoCA-4 were generated using CORINA v3.44 software.[45] Molecules were 
then freely docked in the colchicine binding site between chains C and D from PDB structure 1SA0 using GOLD v5.1 
software.[46] CHEMPLP with default parameters was used as an objective function.[47] Structures of the complexes 
were exported for further examination and depiction with Chimera v1.8.1 software,[48] including hydrogen bonds 
detection, close contact analysis and representation of the solvent-accessible surface colored according to polarity. 
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